HIND
Vyome Holdings, Inc.·Healthcare
2.24
3.030%(−0.07)
Close PriceLast Updated: — ET
52W L: $1.7552W H: $33.16
HIND NEWS
businesswire.com
May 12
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced the signing of an agreement with Impetis Biosciences Limited (“Impetis”), a TATA Enterprise, that gives it exclusive license to develop and commercialize a selective JAK 1/3 inhibitor and a selective JAK1 inhibitor. Janus kinase (JAK) inhibitors are immunomodulatory drugs that treat autoimmune and inflammatory conditions by blocking JAK enzymes. Several JAK inhibitors are FDA-approved to treat a wid.
businesswire.com
Apr 22
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026.
businesswire.com
Apr 6
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Holdings, Inc. (“Vyome”) (Nasdaq: HIND) today announced that the company will present its full Phase 2 investigator initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor and other symptoms of Malignant Fungating Wounds (“MFW”) at the 2026 American Association for Cancer Research (AACR) Annual Meeting, taking place on April 17-22, 2026, in San Diego. Venkat Nelabhotla, CEO of Vyome,.
businesswire.com
Mar 26
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase.
